secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001104659-23-087631
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec Q2 revenue $3.3M (up 98% QoQ); appoints Adrian Haigh as COO
------------------------------------------------------------------

- Net product sales of $3.3M for Q2 2023, up 98% from Q1 2023; gross profit $3.2M.
- Net loss of $5.4M ($0.21 diluted EPS) vs $5.1M loss ($0.19) in Q2 2022.
- Cash and equivalents $15.0M; sufficient to fund operations for at least 12 months.
- Adrian Haigh appointed COO, stepping down from board; base salary €400K/yr plus bonus and 200K options.
- Management to present at 2023 Wedbush PacGrow Healthcare Conference on August 8-9.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923087631/0001104659-23-087631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923087631/tm2322902d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-087631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer